Pfizer Inc.
$26.9
▼
-1.5%
2026-04-22 10:12:13
www.pfizer.com
NYQ: PFE
Explore Pfizer Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$152.79 B
Current Price
$26.9
52W High / Low
$28.75 / $21.87
Stock P/E
19.83
Book Value
$15.21
Dividend Yield
6.25%
ROCE
10.17%
ROE
8.89%
Face Value
—
EPS
$1.36
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
75,000
Beta
0.39
Debt / Equity
77.96
Current Ratio
1.16
Quick Ratio
0.87
Forward P/E
9.56
Price / Sales
2.45
Enterprise Value
$207.42 B
EV / EBITDA
8.06
EV / Revenue
3.31
Rating
Buy
Target Price
$28.58
EPS Forecast (FY)
—
Pros
- Strong operating margin profile.
- Net margin remains healthy.
- Meaningful dividend yield is available.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Biogen Inc. | $191.44 | 21.83 | $28.09 B | — | 9.46% | 7.39% | $202.41 / $114.66 | $124.36 |
| 2. | AbbVie Inc. | NOT FOUND | 86.59 | $360.82 B | 3.4% | 22.16% | 62.25% | $244.81 / $168.54 | $-1.85 |
| 3. | Gilead Sciences, Inc. | $133.45 | 19.68 | $165.41 B | 2.41% | 24.79% | 40.66% | $157.29 / $93.37 | $18.29 |
| 4. | Organon & Co. | $9.26 | 12.89 | $2.41 B | 0.86% | 11.7% | 30.56% | $13.24 / $5.69 | $2.89 |
| 5. | Nasus Pharma Ltd. | $2.86 | — | $19.29 M | — | -172.62% | 2637.84% | $9.99 / $1.98 | $0.31 |
| 6. | AstraZeneca PLC | $196.47 | 30 | $305.64 B | 1.58% | 15.97% | 22.84% | $15,730 / $9,651 | $31.38 |
| 7. | Eli Lilly and Company | $921 | 40.12 | $868.52 B | 0.75% | 38.44% | 1.01% | $1,133.95 / $623.78 | $29.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 17.56 B | 16.65 B | 14.65 B | 13.71 B | 17.76 B | — |
| Operating Profit | 3.69 B | 5.53 B | 3.77 B | 4.42 B | 3.19 B | — |
| Net Profit | -1.65 B | 3.54 B | 2.91 B | 2.97 B | 410 M | — |
| EPS in Rs | -0.29 | 0.62 | 0.51 | 0.52 | 0.07 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 62.58 B | 63.63 B | 59.55 B | 101.17 B |
| Operating Profit | 17.41 B | 14.94 B | 4.42 B | 38.12 B |
| Net Profit | 7.77 B | 8.03 B | 2.12 B | 31.37 B |
| EPS in Rs | 1.37 | 1.41 | 0.37 | 5.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 208.16 B | 213.4 B | 226.5 B | 197.21 B |
| Total Liabilities | 121.39 B | 124.9 B | 137.21 B | 101.29 B |
| Equity | 86.48 B | 88.2 B | 89.01 B | 95.66 B |
| Current Assets | 42.9 B | 50.36 B | 43.33 B | 51.26 B |
| Current Liabilities | 36.98 B | 42.99 B | 47.79 B | 42.14 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 11.7 B | 12.74 B | 8.7 B | 29.27 B |
| Investing CF | -1.35 B | 2.65 B | -32.28 B | -15.78 B |
| Financing CF | -10.3 B | -17.14 B | 26.07 B | -14.83 B |
| Free CF | 9.07 B | 9.84 B | 4.79 B | 26.03 B |
| Capex | -2.63 B | -2.91 B | -3.91 B | -3.24 B |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 6.84% | -41.14% | — | — |
| Earnings Growth % | 279% | -93.25% | — | — |
| Profit Margin % | 12.62% | 3.56% | 31.01% | — |
| Operating Margin % | 23.48% | 7.42% | 37.67% | — |
| Gross Margin % | 71.94% | 58.1% | 66.05% | — |
| EBITDA Margin % | 28.49% | 16.05% | 40.55% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-01-23 | $0.43 |
| 2025-11-07 | $0.43 |
| 2025-07-25 | $0.43 |
| 2025-05-09 | $0.43 |
| 2025-01-24 | $0.43 |
Stock Splits
No stock split history available.